XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
N
N

Novartis

市场新闻

Reuters - 5天前

Why gene therapy for sickle cell is slow to catch on with patients

INSIGHT-Why gene therapy for sickle cell is slow to catch on with patients By Deena Beasley LOS ANGELES, Sept 28 (Reuters) - Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain earlier this month. She is doing what she can to prevent the crippling attacks in her arms, legs and abdomen that are becoming more frequent.
N
P
V
Reuters - 6天前

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

UPDATE 1-Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision Adds FDA statement in paragraph 4 By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
N
P
V
Reuters - 6天前

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
N
P
V
Reuters - 1周前

Generate:Biomedicines Announces Multi-Target Collaboration With Novartis To Discover & Develop Protein Therapeutics With Generative Ai

BRIEF-Generate:Biomedicines Announces Multi-Target Collaboration With Novartis To Discover & Develop Protein Therapeutics With Generative Ai Sept 24 (Reuters) - Novartis AG NOVN.S : GENERATE:BIOMEDICINES: ANNOUNCES MULTI-TARGET COLLABORATION WITH NOVARTIS TO DISCOVER & DEVELOP PROTEIN THERAPEUTICS WITH GENERATIVE AI GENERATE:BIOMEDICINES - POTENTIA
N
Reuters - 2周前

Sanofi's tolebrutinib drug delays progressive MS by 31% in trial

UPDATE 1-Sanofi's tolebrutinib drug delays progressive MS by 31% in trial Adds details and background throughout By Ludwig Burger FRANKFURT, Sept 20 (Reuters) - Sanofi SASY.PA said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
N
R
S
Reuters - 2周前

Swiss trade surplus at CHF 4.578 bln in August

TABLE-Swiss trade surplus at CHF 4.578 bln in August Sept 19 (Reuters) - Switzerland ran a merchandise trade surplus of 4.578 billion Swiss francs in August, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) August 2024 July 2024 Imports 15.912 19.215 Exports 20.491 24.092 Balance 4.578 4.877 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S
Reuters - 2周前

Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies

BUZZ-Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies ** Vontobel estimates the market potential for obesity drugs in the U.S. to reach a three-digit billion U.S. dollar amount and picks Swiss Re SRENH.S and Ypsomed YPSN.S as the most likely to profit from it ** Among Swiss life insurers, Swiss Re could benefit the most from a rising demand in life and health reinsurance, with a market share of about 15%, as obesity drugs improve life expectancy, it says ** Its posit
B
H
N
R
S
S
Z
Reuters - 2周前

Novartis: New Data In Relapsing MS Reinforce Benefits Of Kesimpta For First-Line And Switch Patients

BRIEF-Novartis: New Data In Relapsing MS Reinforce Benefits Of Kesimpta For First-Line And Switch Patients Sept 18 (Reuters) - Novartis AG NOVN.S : NEW NOVARTIS DATA IN RELAPSING MS REINFORCE BENEFITS OF KESIMPTA® FOR FIRST-LINE AND SWITCH PATIENTS NEARLY 90% OF FIRST-LINE KESIMPTA PATIENTS HAD NO DISABILITY PROGRESSION INDEPENDENT OF RELAPSE ACTI
N
Reuters - 2周前

Swiss stocks - Factors to watch on September 18

Swiss stocks - Factors to watch on September 18 ZURICH/GDANSK, Sept 18 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: MEYER BURGER TECHNOLOGY AG MBTN.S The company said it has planned the streamlining of its group structure and the reduction of its workforce. NOVARTIS AG NOVN.S FDA approves Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer.
N
Reuters - 2周前

Novartis Says FDA Approves Kisqali To Reduce Risk Of Recurrence In People With HR+/Early Breast Cancer

BRIEF-Novartis Says FDA Approves Kisqali To Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer Sept 17 (Reuters) - Novartis AG NOVN.S : FDA APPROVES NOVARTIS KISQALI® TO REDUCE RISK OF RECURRENCE IN PEOPLE WITH HR+/HER2- EARLY BREAST CANCER Source text for Eikon: ID:nGNEVXqGz Further company coverage: NOVN.S
N
Reuters - 2周前

Novartis Novartis Kisqali® Shows Deepening Benefit In New Analysis, Reducing Risk Of Recurrence By 28.5% In A Broad Population Of Patients With Early Breast Cancer

BRIEF-Novartis Novartis Kisqali® Shows Deepening Benefit In New Analysis, Reducing Risk Of Recurrence By 28.5% In A Broad Population Of Patients With Early Breast Cancer Novartis AG NOVN.S : : NOVARTIS KISQALI® SHOWS DEEPENING BENEFIT IN NEW ANALYSIS, REDUCING RISK OF RECURRENCE BY 28.5% IN A BROAD POPULATION OF PATIENTS WITH EARLY BREAST CANCER
N
Reuters - 3周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds price and availability in paragraph 4 Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R
Reuters - 3周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R
Reuters - 3周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R
Reuters - 3周前

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R
Reuters - 3周前

BMW, Legrand, Sodexo

EUROPE RESEARCH ROUNDUP- BMW, Legrand, Sodexo Sept 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including BMW, Legrand and Sodexo, on Wednesday. HIGHLIGHTS * BMW BMWG.DE : HSBC cuts target price to EUR 85 from EUR 109 * Kion Group AG KGX.DE : JP Morgan raises to overweight from neutral * Legrand LEGD.PA : JP Morgan raises to overweight from neutral * Phoenix PHNX.L : Peel Hunt cuts target price to 650p from 690p * Sodexo EXHO.PA : JP M
A
A
A
A
B
C
E
E
E
G
I
K
L
L
M
N
P
R
S
S
T
U
V
W
E
Reuters - 3周前

Relay Therapeutics' combo therapy cuts breast cancer progression in early study

UPDATE 1-Relay Therapeutics' combo therapy cuts breast cancer progression in early study Adds shares in paragraph 1 By Mariam Sunny and Sneha S K Sept 9 (Reuters) - Relay Therapeutics RLAY.O said on Monday interim data from an early-stage study of its combination drug for breast cancer showed it meaningfully extended the time patients lived without the disease worsening, sending shares surging about 37% in early trading.
A
N
Reuters - 3周前

Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study

Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study By Mariam Sunny and Sneha S K Sept 9 (Reuters) - Relay Therapeutics RLAY.O said on Monday interim data from an early-stage study of its experimental combination treatment for breast cancer showed it meaningfully extended the time patients lived without their disease worsening.
A
N
Reuters - 4周前

Judge won't block Maryland law mandating discounts for hospitals' outside pharmacies

Judge won't block Maryland law mandating discounts for hospitals' outside pharmacies By Brendan Pierson Sept 6 (Reuters) - The largest U.S. drug industry group and several drug companies have lost a bid to block a Maryland law requiring drugmakers to offer discounts on drugs dispensed by third-party pharmacies that contract with hospitals and clinics serving low-income populations.
A
N
Reuters - 4周前

U.S. STOCKS MarketAxess, Perpetua Resources, Sotera Health

BUZZ-U.S. STOCKS ON THE MOVE-MarketAxess, Perpetua Resources, Sotera Health Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's three main indexes slipped in choppy trading on Thursday as a short-lived boost from a services activity survey fizzled out ahead of an upcoming employment report.
J
N
N
T
V
U
D
U
U
M
S
Z
F

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。